HKUMed finds 52% and 66% death reduction for molnupiravir and nirmatrelvir-ritonavir users among inpatients with COVID-19; supports early use of oral antivirals in this population of patients

HKUMed finds 52% and 66% death reduction for molnupiravir and nirmatrelvir-ritonavir users among inpatients with COVID-19; supports early use of oral antivirals in this population of patients

https://www.med.hku.hk/en/news/press/20221003-molnupiravir-nirmatrelvir-ritonavi (English)

https://www.med.hku.hk/zh-hk/news/press/20221003-molnupiravir-nirmatrelvir-ritonavi (Chinese)

HKUMed finds risk of myocarditis in adolescents significantly reduced after receiving only one dose of Comirnaty; adolescents urged to get the first dose of COVID-19 vaccine

HKUMed finds risk of myocarditis in adolescents significantly reduced after receiving only one dose of Comirnaty; adolescents urged to get the first dose of COVID-19 vaccine

Click to view full text of Press Release

Media coverage:

The Standard Online

Date: January 25, 2022

Topic: Single BioNTech jab significantly reduces myocarditis risk for teens – HKU research

Link: https://bit.ly/3u7C3MS

RTHK Chinese Instant News

Date: January 25, 2022

Topic: 青少年延長至少三個月打第二針復必泰可降心肌炎機會

Link: https://bit.ly/3r2pG2D

RTHK Chinese Instant News

Date: January 25, 2022

Topic: 學者建議 12 歲或以上青少年盡快接種第一劑疫苗

Link: https://bit.ly/3G19dA5

CRHK Instant News

Date: January 25, 2022

Topic: 港大研究：青少年接種 2 劑復必泰後 患心肌炎風險較接種 1 劑高 6 倍

Link: https://bit.ly/3AOT4wV

Now TV News

Date: January 25, 2022

Topic: 港大：僅打一針復必泰可大幅降低青少年患心肌炎機會

Link: https://bit.ly/3G51r8j

Ming Pao Instant News

Date: January 25, 2022

Topic: 港大研究：12 歲以上青少年打兩針復必泰 患心肌炎風險為打一針 7 倍

Link: https://bit.ly/3KPezBY

on.cc Instant News

Date: January 25, 2022

Topic: 青少年接種復必泰後 3 周打第二針 患心肌炎風險增逾 7 倍

Link: https://bit.ly/3H502jj

HKEJ Instant News

Date: January 25, 2022

Topic: 港大:青少年打一針復必泰大幅減患心肌炎機會

Link: https://bit.ly/3G9KiKB

Wen Wei Po Instant News

Date: January 25, 2022

Topic: 【抗擊新冠肺炎】港大籲青少年首針後隔 3 個月再打

Link: https://bit.ly/3fXbMbY

am730 Instant News

Date: January 26, 2022

Topic: 青少年打復必泰二針 港大建議隔 3 個月

Link: https://bit.ly/3tXMXou

Sky Post Instant News

Date: January 25, 2022

Topic: 新冠疫苗｜兒童染疫失嗅覺險釀火警 專家指勿輕視後遺症 籲快打針

Link: https://bit.ly/3r3ztWk

Sky Post Instant News

Date: January 26, 2022

Topic: 青少年推遲次針復必泰 降心肌炎風險

Link: https://bit.ly/3IMol6p

HK01

Date: January 25, 2022

Topic: 復必泰｜港大：青少年打第一針 隔 3 個月打第二針可降心肌炎風險

Link: https://bit.ly/3u3SGZK

Topick.hket.com

Date: January 25, 2022

Topic: 【疫苗接種】港大研究發現青少年接種 2 劑復必泰患心肌炎風險較接種 1 劑高 6 倍 建議延長 3 個月後再打

Link: https://bit.ly/3IxxKhY

etnet

Date: January 25, 2022

Topic: 【新冠肺炎】研究：青少年接種１劑復必泰，患心肌炎風險較兩劑低

Link: https://bit.ly/3r1GtTF

Hkcna.hk

Date: January 25, 2022

Topic: 港大研究：僅打一針復必泰可降低青少年患心肌炎機會

Link: https://bit.ly/3HhSREw

Udn.com (Taiwan)

Date: January 26, 2022

Topic: 香港研究稱：青少年 2 劑 BNT 心肌炎風險較 1 劑高 6 倍

Link: https://bit.ly/3g12lZ1

Facing the dilemma between unmet needs and costly drugs: what are the strategic solutions for rare diseases?

Dr Shirley Li spoke as a panelist at the WHO webinar series on country pharmaceutical pricing policies and presented the “Global Access and Unmet Needs of Orphan Drugs” based on the team’s previous work published in Value in Health.

Click to view the full text of paper

HKUMed achieves a breakthrough in retinoblastoma treatment by a light-triggered drug release system

HKUMed achieves a breakthrough in retinoblastoma treatment by a light-triggered drug release system

Click to view full version (English)

Click to view full version (Chinese)

HKUMed develops inhaled dry powder formulation of broad-spectrum antiviral against COVID-19 and influenza

HKUMed develops inhaled dry powder formulation of broad-spectrum antiviral against COVID-19 and influenza

Click to view full version

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

HKUMed discovers a novel mediator of liver fibrosis and its underlying mechanism that can be a new therapeutic target

Click to view full version

HKUMed takes leading role in the largest cohort study on global hip fracture burden

HKUMed takes leading role in the largest cohort study on global hip fracture burden